CMPS Latest Headlines

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), COMPASS Pathways (CMPS) and NRX Pharmaceuticals (NRXP)

at www.tipranks.com (Wed, 4-Nov 10:41 AM)

Compass Pathways’ Regulatory Progress and COMP360 Launch Readiness Support Buy Rating; $25 Price Target Unchanged

at www.tipranks.com (Wed, 4-Nov 9:07 AM)

Wells Fargo Sticks to Their Hold Rating for COMPASS Pathways (CMPS)

at www.tipranks.com (Wed, 4-Nov 9:00 AM)

RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

at www.tipranks.com (Wed, 4-Nov 8:56 AM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Wed, 4-Nov 8:50 AM)

Compass Pathways Spotlights the Human Cost of Treatment-Resistant Depression in New National Survey

Market Chameleon (Tue, 3-Nov 11:38 AM)

CMPS targets an NDA filing within two weeks as it builds launch readiness for a potential H1 2027 debut

Market Chameleon (Tue, 3-Nov 7:07 AM)

COMPASS Pathways rebounds on earnings after selloff driven by rival’s NDA submission

at seekingalpha.com (Tue, 3-Nov 8:41 AM)

COMPASS Pathways ADS GAAP EPS of -$0.31 beats by $0.10

at seekingalpha.com (Tue, 3-Nov 6:38 AM)

Here are the major earnings before the open Tuesday

at seekingalpha.com (Mon, 2-Nov 6:00 PM)

COMPASS Pathways ADS Q3 2026 Earnings Preview

at seekingalpha.com (Mon, 2-Nov 10:10 AM)

Compass Pathways’ Phase 3 Data Sets Stage for COMP360 Launch and Blockbuster Potential in TRD

Market Chameleon (Wed, 5-Aug 7:42 AM)